Clareo Health | A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
40–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients 40-70 years of age, inclusive.
Body Mass Index 18-32 kg/m2, inclusive.
Female patients must be surgically sterile or post menopausal for the past year confirmed by a negative hormone panel. Male patients and their partners of childbearing potential must use two methods of contraception, one of which must be a barrier method for the duration of the study and for 7 days after last dose.
Diagnosis of moderate-to-severe COPD (GOLD Stage II-III).
You may not be if
Current smoker or history of smoking in the last three months.
Use of continuous daily long term oxygen therapy or requirement for oxygen therapy during exercise.
History of cardiac conduction abnormalities or ventricular tachyarrhythmias.
Exacerbation of COPD within 8 weeks before first dosing.
